It has been found that ADM productivity as well as MMP1 productivity and/or HGF productivity can be enhanced by causing cardiac stem cells to express specific factors. In addition, due to the finding that such cardiac stem cells have excellent immunoregulatory and/or anti-inflammatory abilities, it was possible to provide a cell population containing such cardiac stem cells.
It is found that fibroblasts can suppress kidney fibrosis and can recover the function of the kidney in a rat model with a kidney disease. As a result, a pharmaceutical composition for treating a kidney disease which contains fibroblasts can be provided.
It is found that fibroblasts can suppress kidney fibrosis and can recover the function of the kidney in a rat model with a kidney disease. As a result, a pharmaceutical composition for treating a kidney disease which contains fibroblasts can be provided.
ADM and/or HHEX-highly expressing fibroblasts have been found as cells having lymphangiogenesis ability, and a means for treating fibrosis using a pharmaceutical composition containing said cells, a means for ameliorating a state in which the lymphangiogenesis ability deteriorates, and a means for maintaining the homeostasis of a tissue fluid, transporting lipid and/or vitamin, regulating immunological surveillance, or treating organ failure have been found. Moreover, it has been found that ADM-highly expressing and VCAM-1 expression-improving fibroblasts derived from an adult are obtained by culturing human fibroblasts using a culture medium to which TNF-a and IL-4 are added, and the provision of ADM-highly expressing fibroblasts and a means for treating lung diseases using said cells have been found.
ADM and/or HHEX-highly expressing fibroblasts have been found as cells having lymphangiogenesis ability, and a means for treating fibrosis using a pharmaceutical composition containing said cells, a means for ameliorating a state in which the lymphangiogenesis ability deteriorates, and a means for maintaining the homeostasis of a tissue fluid, transporting lipid and/or vitamin, regulating immunological surveillance, or treating organ failure have been found. Moreover, it has been found that ADM-highly expressing and VCAM-1 expression-improving fibroblasts derived from an adult are obtained by culturing human fibroblasts using a culture medium to which TNF-α and IL-4 are added, and the provision of ADM-highly expressing fibroblasts and a means for treating lung diseases using said cells have been found.
By culturing a human fibroblast using a culture medium supplemented with TNF-a and IL-4, it is found that the EPO production ability in the fibroblast can be improved. As the result of the finding, a fibroblast having an enhanced EPO production ability is discovered, and a means for improving an EPO production-decreased state or a means for treating a renal disorder or renal anemia using the cell is also discovered.
By culturing a human fibroblast using a culture medium supplemented with TNF-α and IL-4, it is found that the EPO production ability in the fibroblast can be improved. As the result of the finding, a fibroblast having an enhanced EPO production ability is discovered, and a means for improving an EPO production-decreased state or a means for treating a renal disorder or renal anemia using the cell is also discovered.
Provided is a method for producing a CD106-positive and/or CD90-positive fibroblast. Also provided is a G-CSF-positive fibroblast mass. A method for producing a CD106-positive and/or CD90-positive fibroblast, comprising the step of culturing a fibroblast in the presence of at least one component selected from the group consisting of TNF-α and IL-4 to increase the number of CD106-positive and/or CD90-positive fibroblasts.
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 9/04 - Agents inotropes, c.-à-d. stimulants de la contraction cardiaqueMédicaments pour le traitement de l'insuffisance cardiaque
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
9.
METHOD FOR PRODUCING FIBROBLAST, AND G-CSF-POSITIVE FIBROBLAST MASS
Provided is a method for producing a CD106-positive and/or CD90-positive fibroblast. Also provided is a G-CSF-positive fibroblast mass. A method for producing a CD106-positive and/or CD90-positive fibroblast, comprising the step of culturing a fibroblast in the presence of at least one component selected from the group consisting of TNF-a and IL-4 to increase the number of CD106-positive and/or CD90-positive fibroblasts.
C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
10.
COMPOSITION FOR INJECTION WHICH CAN BE USED FOR TREATMENT OF HEART DISEASES AND CONTAINS FIBROBLASTS, AND METHOD FOR PRODUCING FIBROBLAST FOR THERAPY USE
The present invention addresses the problem of providing a useful technique for healing a dead cardiac tissue region thoroughly over a long period to recover the function of the heart, which has not yet been established. The problem can be solved by a composition for injection which contains fibroblasts and can be used for the treatment of heart diseases, wherein the fibroblasts includes CD106-positive fibroblasts, preferably CD90-positive fibroblasts.
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
A61P 9/04 - Agents inotropes, c.-à-d. stimulants de la contraction cardiaqueMédicaments pour le traitement de l'insuffisance cardiaque
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
11.
COMPOSITION FOR INJECTION WHICH CAN BE USED FOR TREATMENT OF HEART DISEASES AND CONTAINS FIBROBLASTS, AND METHOD FOR PRODUCING FIBROBLAST FOR THERAPY USE
The present invention addresses the problem of providing a useful technique for healing a dead cardiac tissue region thoroughly over a long period to recover the function of the heart, which has not yet been established. The problem can be solved by a composition for injection which contains fibroblasts and can be used for the treatment of heart diseases, wherein the fibroblasts includes CD106-positive fibroblasts, preferably CD90-positive fibroblasts.
A61P 9/04 - Agents inotropes, c.-à-d. stimulants de la contraction cardiaqueMédicaments pour le traitement de l'insuffisance cardiaque
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
The purpose of the present invention is to provide a cardiac cell culture material which specifically acts on cardiac cells. In addition, another purpose of the present invention is to provide artificial organ material obtained by culturing by using said cardiac cell culture material, and a method for producing the same. Thus, provided is a cardiac cell culture, wherein functional cardiac tissue is favorably built by using a cardiac cell culture material containing VCAM-1.
C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
The purpose of the present invention is to provide a cardiac cell culture material which specifically acts on cardiac cells. In addition, another purpose of the present invention is to provide artificial organ material obtained by culturing by using said cardiac cell culture material, and a method for producing the same. Thus, provided is a cardiac cell culture, wherein functional cardiac tissue is favorably built by using a cardiac cell culture material containing VCAM-1.
C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
brevets
